Stemline Therapeutics Reports Third Quarter 2019 Financial Results
November 07, 2019 16:57 ET
|
Stemline Therapeutics, Inc.
Net revenue for ELZONRIS® was $13.3 million for the third quarterNew patient starts estimated to have increased greater than 20% from last quarterConference call and live webcast scheduled for...
Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting
November 06, 2019 09:15 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results on November 8, 2019
November 05, 2019 16:22 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology
October 08, 2019 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress
October 01, 2019 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress
September 27, 2019 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
September 26, 2019 16:01 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference
September 18, 2019 09:32 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 05, 2019 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
August 09, 2019 16:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...